AZAFAROS
Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
AZAFAROS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2018-04-05
Address:
Leiden, Zuid-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.azafaros.com
Total Employee:
11+
Status:
Active
Contact:
+31 (0) 35 699 30 00
Email Addresses:
[email protected]
Total Funding:
25 M EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Font Awesome Person Schema Gravatar Profiles GStatic Google Static Content
Similar Organizations
Aardvark Therapeutics
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Kodiak Sciences
Kodiak is designing and developing novel therapies for the treatment of retinal disease.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Current Employees Featured
Founder
Investors List
BioGeneration Ventures
BioGeneration Ventures investment in Series A - Azafaros
Forbion Capital Partners
Forbion Capital Partners investment in Series A - Azafaros
BioMedPartners
BioMedPartners investment in Series A - Azafaros
BioGeneration Ventures
BioGeneration Ventures investment in Seed Round - Azafaros
Key Employee Changes
| Date | New article |
|---|---|
| 2023-03-20 | Azafaros Appoints Chief Operating Officer and Head of Finance |
Official Site Inspections
http://www.azafaros.com Semrush global rank: 5.83 M Semrush visits lastest month: 1.21 K
- Host name: managed343.cloud86-host.io
- IP address: 45.82.191.220
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
More informations about "Azafaros"
About us | Azafaros B.V.
Founded in 2018, Azafaros has leveraged on decades of discovery by professors Hans Aerts, Hermen Overkleeft, and Stan van Boeckel at Leiden University and the Academic Medical …See details»
Azafaros - Crunchbase Company Profile & Funding
Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents …See details»
AZAFAROS B.V. - LinkedIn
Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with ...See details»
Azafaros BV - Drug pipelines, Patents, Clinical trials - Synapse
Azafaros is supported by a syndicate of leading Dutch and Swiss investors including Forbion, BioGeneration Ventures, BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders …See details»
Azafaros - Funding, Financials, Valuation & Investors - Crunchbase
Azafaros aims at developing new therapeutic agents for the treatment of rare metabolic disorders. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much funding has …See details»
Azafaros - VentureRadar
Azafaros B.V. is a biopharmaceutical company focused on developing innovative treatments for rare diseases affecting the central nervous system. Their lead clinical candidate, …See details»
Story and Mission | Azafaros B.V.
Founded in 2018, Azafaros has leveraged on decades of discovery by professors Hans Aerts, Hermen Overkleeft, and Stan van Boeckel at Leiden University and the Academic Medical …See details»
Patient Resources and Organizations | Azafaros B.V.
At Azafaros, we value highly the important work of patient-focused organizations and communities. Through close collaborations and partnerships, our goal is to understand …See details»
Azafaros B.V. at the Swiss Biotech Day
Azafaros is a clinical-stage biotech company addressing rare genetic lysosomal storage disorders with oral small molecules, including our lead asset, nizubaglustat. Our focus is on developing …See details»
Azafaros - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Nov 10, 2024 Organization. Azafaros . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 5. Monthly …See details»
Azafaros Switzerland AG - Swiss Biotech
Azafaros is a clinical-stage biotech addressing rare genetic lysosomal storage disorders with oral small molecules, including nizubaglustat. Our focus is on developing disease-modifying …See details»
European rare disease biotech Azafaros grabs $28M early funding …
Feb 6, 2020 Azafaros has grabbed €25 million ($27.5 million) in a series A investment boost as it looks to push on with its pipeline focused on rare metabolic disorders. | Azafaros has grabbed …See details»
Connect with Azafaros | Azafaros B.V.
Azafaros B.V. Gooimeer 2-35 1411 DC Naarden The Netherlands Azafaros Switzerland AG Dufourstrasse 25 4052 Basel Switzerland. Your name E-mail Telephone number: Question or …See details»
Azafaros - Overview, News & Similar companies | ZoomInfo.com
Jan 22, 2024 Who is Azafaros. Founded in 2018 with a deep understanding of rare genetic disease mechanisms and led by a team of highly experienced industry experts, Azafaros aim s …See details»
Azafaros - Contacts, Employees, Board Members, Advisors & Alumni
Azafaros aims at developing new therapeutic agents for the treatment of rare metabolic disorders.See details»
Azafaros announces completion of 12-week Phase 2 RAINBOW …
Mar 12, 2024 Leiden, The Netherlands, March 12, 2024 – Azafaros B.V. today announced the completion of its 12-week Phase 2 clinical study, RAINBOW (Phase 2 RAINBOW study …See details»
Board of Directors | Azafaros B.V.
Edward van Wezel Non-Executive Board Member. Founder and Managing Partner at BioGeneration VenturesSee details»
Working at Azafaros - Glassdoor
Glassdoor gives you an inside look at what it's like to work at Azafaros, including salaries, reviews, office photos, and more. This is the Azafaros company profile. All content is posted …See details»
Azafaros Appoints Stefano Portolano, M.D., as Chief Executive Officer
Jun 30, 2021 Since the company’s inception in 2018, Azafaros has made remarkable progress by building a strong and committed organization that has reached the clinic in less than three …See details»